Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Domenico Lepore

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Journal of Clinical Microbiology|April 18, 2013
Why should we monitor (1-3)-β-D-glucan levels during invasive candidiasis? Just ask your ophthalmologist!Gennaro De Pascale, Brunella Posteraro, Salvatore Lucio Cutuli, et al.
Eclinicalmedicine|April 19, 2024
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trialNeil Marlow, James D Reynolds, Domenico Lepore, et al.
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|January 28, 2012
Analysis of risk factors for progression to treatment-requiring ROP in a single neonatal intensive care unit: is the exposure time relevant?Carmen Giannantonio, Patrizia Papacci, Francesco Cota, et al.
Translational Vision Science & Technology|August 29, 2020
Convolutional Neural Network Based on Fluorescein Angiography Images for Retinopathy of Prematurity ManagementDomenico Lepore, Marco H Ji, Monica M Pagliara, et al.
Ophthalmology|July 9, 2014
Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findingsDomenico Lepore, Graham E Quinn, Fernando Molle, et al.
Ophthalmology|September 5, 2017
Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic FindingsDomenico Lepore, Graham E Quinn, Fernando Molle, et al.
Ophthalmology. Retina|September 3, 2019
Retinopathy of Prematurity Reactivated 28 Months after Injection of RanibizumabMarco H Ji, Darius M Moshfeghi, Natalia F Callaway, et al.
European Journal of Ophthalmology|July 30, 2020
Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effectMarco H Ji, Darius M Moshfeghi, Ryan A Shields, et al.
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus|November 2, 2010
Occipital porencephaly in a child with gyrate atrophy of the choroid and retinaDonato Rigante, Maria Cristina Savastano, Antonio Leone, et al.
Lancet (London, England)|September 17, 2019
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trialAndreas Stahl, Domenico Lepore, Alistair Fielder, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Journal of Clinical Microbiology|April 18, 2013
Why should we monitor (1-3)-β-D-glucan levels during invasive candidiasis? Just ask your ophthalmologist!Gennaro De Pascale, Brunella Posteraro, Salvatore Lucio Cutuli, et al.
Eclinicalmedicine|April 19, 2024
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trialNeil Marlow, James D Reynolds, Domenico Lepore, et al.
The Journal of Maternal-Fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians|January 28, 2012
Analysis of risk factors for progression to treatment-requiring ROP in a single neonatal intensive care unit: is the exposure time relevant?Carmen Giannantonio, Patrizia Papacci, Francesco Cota, et al.
Translational Vision Science & Technology|August 29, 2020
Convolutional Neural Network Based on Fluorescein Angiography Images for Retinopathy of Prematurity ManagementDomenico Lepore, Marco H Ji, Monica M Pagliara, et al.
Ophthalmology|July 9, 2014
Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findingsDomenico Lepore, Graham E Quinn, Fernando Molle, et al.
Ophthalmology|September 5, 2017
Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic FindingsDomenico Lepore, Graham E Quinn, Fernando Molle, et al.
Ophthalmology. Retina|September 3, 2019
Retinopathy of Prematurity Reactivated 28 Months after Injection of RanibizumabMarco H Ji, Darius M Moshfeghi, Natalia F Callaway, et al.
European Journal of Ophthalmology|July 30, 2020
Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effectMarco H Ji, Darius M Moshfeghi, Ryan A Shields, et al.
Journal of AAPOS : the Official Publication of the American Association for Pediatric Ophthalmology and Strabismus|November 2, 2010
Occipital porencephaly in a child with gyrate atrophy of the choroid and retinaDonato Rigante, Maria Cristina Savastano, Antonio Leone, et al.
Lancet (London, England)|September 17, 2019
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trialAndreas Stahl, Domenico Lepore, Alistair Fielder, et al.
Pageof 5